Novo Nordisk's Wegovy Slashes Liver Fat to Normal in 90% of Obese…

Event summary

Wegovy (semaglutide) reduced liver fat to normal levels in 88.5% of participants with elevated liver fat after 72 weeks.
Liver fat decreased from 8.8% to 3.1% in the treatment group, per MRI data from the STEP UP trial sub-population.
Findings presented at EASD 2026 highlight Wegovy's potential to address early-stage liver disease in obesity patients.
STEP UP pooled analysis included 1,919 adults, with 55 having excess liver fat at baseline.
Semaglutide 2.4 mg is approved for MASH treatment in multiple markets, including the U.S. and China.

The big picture

Novo Nordisk's findings underscore the growing intersection of obesity and liver disease treatment, where GLP-1 agonists like Wegovy are emerging as multi-faceted therapeutic tools. The results strengthen Novo's position in the cardiometabolic space, where addressing co-morbidities is increasingly critical for long-term patient management. With semaglutide already approved for MASH in key markets, this data could accelerate adoption in earlier-stage liver disease prevention.

What we're watching

Therapeutic Expansion: Whether Novo Nordisk can leverage these results to expand Wegovy's indications beyond obesity and into liver disease prevention.
Market Differentiation: How this data positions Wegovy against competitors in the GLP-1 receptor agonist space, particularly for metabolic disease comorbidities.
Regulatory Pathways: The pace at which Novo Nordisk advances semaglutide 2.4 mg through MASH trials and potential new approvals.